Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway
Citation Manager Formats
Make Comment
See Comments

Abstract
Background and Objectives Demyelinating diseases in the CNS are characterized by myelin sheath destruction or formation disorder that leads to severe neurologic dysfunction. Remission of such diseases is largely dependent on the differentiation of oligodendrocytes precursor cells (OPCs) into mature myelin-forming OLGs at the demyelinated lesions, which is defined as remyelination. We discover that baicalin (BA), a natural flavonoid, in addition to its well-known antiinflammatory effects, directly stimulates OLG maturation and CNS myelin repair.
Methods To investigate the function of BA on CNS remyelination, we develop the complementary in vivo and in vitro models, including physiologic neonatal mouse CNS myelinogenesis model, pathologic cuprizone-induced (CPZ-induced) toxic demyelination model, and postnatal OLG maturation assay. Furthermore, molecular docking, pharmacologic regulation, and transgenic heterozygous mice were used to clarify the target and action of the mechanism of BA on myelin repair promotion.
Results Administration of BA was not only merely effectively enhanced CNS myelinogenesis during postnatal development but also promoted remyelination and reversed the coordination movement disorder in the CPZ-induced toxic demyelination model. Of note, myelin-promoting effects of BA on myelination or regeneration is peroxisome proliferator-activated receptor γ (PPARγ) signaling-dependent.
Discussion Our work demonstrated that BA promotes myelin production and regeneration by activating the PPARγ signal pathway and also confirmed that BA is an effective natural product for the treatment of demyelinating diseases.
Glossary
- APC=
- adenomatous polyposis coli;
- BA=
- baicalin;
- CGZ=
- ciglitazone;
- CPZ=
- cuprizone;
- EAE=
- experimental autoimmune encephalomyelitis;
- GFAP=
- glial fibrillary acidic protein;
- IBA1=
- ionized calcium binding adapter molecule 1;
- LFB=
- Luxol fast blue;
- MBP=
- myelin basic protein;
- MS=
- multiple sclerosis;
- NC=
- naïve chow;
- NFH=
- neurofilament H;
- NG2=
- chondroitin sulfate proteoglycan 2;
- OLGs=
- oligodendrocytes;
- Olig2=
- oligodendrocyte transcription factor 2;
- OPCs=
- oligodendrocyte precursor cells;
- PBS=
- phosphate-buffered saline;
- PDGFR α=
- platelet-derived growth factor receptor α;
- PEI=
- polysciences;
- PGZ=
- pioglitazone;
- PPARγ=
- peroxisome proliferator-activated receptor γ;
- PPARγ+/-=
- PPARγ deficient heterozygous;
- PPRE=
- peroxisome proliferator element
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
↵* Equal Contributions to this work and are the co–first authors of this paper.
The Article Processing Charge was funded by the authors.
- Received August 19, 2021.
- Accepted in final form December 10, 2021.
- Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.